Free Access
Tableau III
Composés agonistes en cours de développement ciblant TLR8.
| Cible des agonistes | Nom | Compagnie | Indication | Statut de l’essai |
|---|---|---|---|---|
| TLR8 | VTX-1463 | VantiRX Pharmaceuticals Inc. | Rhinite allergique | Phase I |
| TLR8 | VTX-2337 | VantiRX Pharmaceuticals Inc. | Cancer | Phase I |
| TLR7, TLR8 et TLR9 | CPG 52364 | Pfizer | Lupus érythémateux disséminé | Phase I |
| TLR7 et TLR8 | Resiquimod | 3M Pharmaceuticals | Hépatite C, herpès | Suspendu en phase III |
| TLR7 et TLR8 | IMO-4020 | Idera Pharmaceuticals | Lymphome | Préclinique |
| TLR7, TLR8 et TLR9 | Adjuvant vaccinal | Idera Pharmaceuticals | Maladies infectieuses, cancer, maladie d’Alzheimer | Préclinique |
| TLR7 et TLR8 | VTX-463 | Array BioPharma | Allergie | Préclinique |
| TLR8 | VTX-763 | VantiRX Pharmaceuticals Inc. | Inflammation auto-immune | Préclinique |
| TLR7 et TLR8 | IPH 3201 | Innate Pharma | Adjuvant vaccinal | Préclinique |
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.